Celltrion to buy back 100 bln won in shares to boost shareholder value

SEOUL, April 22 (Yonhap) -- Celltrion Inc., a leading South Korean biopharmaceutical company, said Wednesday it plans to repurchase 100 billion won (US$68 million) worth of its own shares as part of its efforts to enhance shareholder value.

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.